Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 637 shares at $26.18 ($17K) on 2024-09-10, disclosed to the SEC on 2024-09-13.
Seasonal sale ($17k) by Chief Development Officer — this insider has traded AKRO in September in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |